

Evidence Summary: Lymphatic filariasis: Prevention

October 2015

Author

Wound Healing and Management Node Group — Emily Haesler

QUESTIONS

What is the best available evidence on preventing the spread of filariasis?

SUMMARY

Lymphatic filariasis is a parasitic infection spread by mosquito in tropical countries. The disease course is primarily asymptomatic but includes episodic acute disease that can become chronic. Prevention of disease is the most effective management strategy. Vector control strategies (for example, mosquito netting) are highly recommended in geographic regions where filariasis is present¹ (Level 4.b evidence). Preventive chemotherapy (albendazole plus either diethylcarbamazine [DEC] or ivermectin)² (Level 1.a evidence) at an individual and/or population level is also highly recommended to prevent the spread of disease.

BACKGROUND

Epidemiology

Lymphatic filariasis is a parasitic infection of threadlike worms that is spread by female mosquito bite. Mosquitoes become infected after feeding on blood from people infected with microfilariae (juvenile worms). When the mosquito moves to another person and feeds, the microfilariae enter the skin and migrate to the lymphatic system where they develop into macrofilariae (mature worms) and continue breeding. The resulting microfilariae then return to the bloodstream. The time frame from infection to production of microfilariae in the blood stream is six to 12 months^{2,3}. Three different roundworms are implicated in lymphatic filariasis, *Wuchereria bancrofti* (found in tropical regions of Africa, Asia, China and Pacific Islands), *Brugia timori* (Asia) and *Brugia malayi* (Indonesia)².

Lymphatic filariasis is endemic in 58 countries, but 80% of people who are at risk of exposure live in one of the following 10 countries: Bangladesh, Côte d'Ivoire, the Democratic Republic of Congo, India, Indonesia, Myanmar, Nigeria, Nepal, the Philippines, and the United Republic of Tanzania⁴.

Clinical presentation

The clinical course of lymphatic filariasis falls into three broad categories: asymptomatic disease, acute phase and chronic disease.

Filariasis is primarily asymptomatic; however, even people without clinical symptoms can experience pathological changes to the lymphatic system with the widening of the lymphatic vessels (lymphangiectasia)². In the acute phase, patients experience sudden, episodic onset of signs and symptoms including fever, enlarged inguinal and axillary lymph nodes (adenolymphangitis), and lymphoedema, with skin exfoliation often occurring at the resolution of an

acute episode^{4,6}. Repeated episodes of acute bacterial adenolymphangitis (ADL) are associated with progression of the severity of lymphatic filariasis⁵. Chronic lymphatic filariasis is characterised by chronic and irreversible lymphoedema and elephantiasis of the limbs, scrotum and breasts^{2,4,6}.

Diagnostic methods include:⁶

- establishing history of exposure;
- antigen detection assay to detect adult worms; and, most reliably
- microfilariae detection using venous blood smears, usually done at night when the microfilariae are most active in the bloodstream.

CLINICAL BOTTOM LINE

Management of lymphatic filariasis aims to reduce the spread of microfilariae at the community level include mass drug administration programs (preventive chemotherapy) and vector control programs^{2,4}.

Vector control

Preventing initial infection by avoiding mosquito bite is the most effective way to prevent lymphatic filariasis. Prevention strategies include:

- sleeping under a mosquito net^{3,4} (Level 5.b evidence);
- covering the skin with clothing (long sleeves and trousers)³ (Level 5.b evidence);
- application of personal mosquito repellent, especially between dusk and dawn³ (Level 5.b evidence); and
- indoor residual spraying of repellent⁴ (Level 5.b evidence).

Additional evidence is provided by a cross-sectional study conducted in Tanzania. Insecticide treated netting was used in conjunction with a population level DEC program (monthly low dose for 12 months) in three villages. Individuals who used insecticide treated netting for the longest period had significantly lower risk of microfilariae prevalence (odds ratio [OR] 0.681, 95% confidence interval [CI] 0.50 to 0.94). The risk of new infections was also reduced by 58.8% (95% CI 30.3 to 5.4)¹ (Level 4.b evidence). It is unclear if there is increased protection associated with insecticide treatment of netting compared with regular mosquito netting.

Preventive chemotherapy

The World Health Organization recommends prevention of filariasis with an annual single dose of combination therapy (albendazole plus either DEC or ivermectin) or six to 12 months of DEC-medicated salt⁷.

The three primary treatments for eradication of microfilariae and macrofilariae and prevention of their spread are albendazole,

ivermectin and DEC, either alone or in combination with each other. Albendazole is used to treat adult worms, DEC is used to treat both adult worms and microfilariae and ivermectin treats microfilariae and may have a role in sterilising adult worms. Medications are generally given in a single dose (albendazole 400 mg, DEC 6 mg/kg body weight or ivermectin 150 to 200 µg/kg body weight)^{2,8-14}.

The evidence on effectiveness of these three chemical treatments has been reported in a comprehensive Cochrane review that included seven randomised controlled trials (RCTs). The trials were conducted in child and adult populations with follow-up varying from three months to two years². The findings, which are presented in more detail below, suggest that there is no significant difference between various chemotherapy regimens in preventing the spread of microfilariae and the review authors indicate that further research is required, particularly on combination regimens that seek to eradicate filariae at both juvenile and adults stages².

DEC-medicated salt is also used in some countries (for example, Guyana, China and Tanzania) at a population level to manage spread of filariasis. Medication is generally added to salt at the point of iodisation at between 0.1% and 1% concentration¹⁵.

The evidence on effectiveness of DEC-medication salt has been reported in a Cochrane review of studies of different methodologies, the findings of which are presented below. The studies included in this review achieved high levels of community coverage; however, the follow-up periods were generally short (one year or less). The findings indicated that the intervention is effective with coverage at 90% for at least six months¹⁵.

Albendazole

- A meta-analysis found no significant difference between albendazole (n=401) compared with placebo (n=382) for microfilariae prevalence in all participants (those who were both positive and negative at baseline) at three-to-four months (risk ratio [RR] 0.95, 95% CI 0.66 to 1.37, p=0.80)². (Level 1.a evidence). In one included RCT, there was also no significant difference between albendazole (n=256) compared with placebo (n=243) at six months (RR 1.00, 95% CI 0.66 to 1.53, p=0.99)¹⁰ (Level 1.c evidence).

Diethylcarbamazine (DEC)

- One RCT found DEC (n=246) was more effective than albendazole (n=256) in reducing microfilariae prevalence in participants who were both positive and negative at baseline at six-month follow-up (RR 1.74, 95% CI 1.05 to 2.88); however, there were no significant differences seen at three- to four-month follow-up¹⁰ (Level 1.c evidence).
- When DEC was combined with albendazole, there was no significant difference compared with DEC alone in reducing microfilariae prevalence in participants who were both positive and negative at baseline (RR 0.62, 95% CI 0.32 to 1.21)¹⁰ (Level 1.c evidence).

Ivermectin

- One RCT found ivermectin (n=145) was not significantly different from albendazole (n=145) for reducing

microfilariae prevalence in participants who were both positive and negative at baseline at six-month follow-up (RR 1.14, 95% CI 0.65 to 1.99)⁸ (Level 1.c evidence).

Diethylcarbamazine (DEC)-medicated salt

- In 21 studies (4 conducted at an individual level and 17 conducted at community level) percentage reduction of microfilariae ranged from 43% to 100%. There was a significant moderate correlation between per capita consumption and reduction in microfilariae prevalence after 12 months (Pearson's correlation coefficient $r=0.642$, $p=0.003$)¹⁵ (Level 1.b evidence).
- A multivariate regression analysis indicated that without DEC-medicated salt intervention the spread of filariasis would increase annually by 11.38%. For each unit increase in DEC concentration there is a 217.78% reduction in annual spread and for each unit of duration of treatment there is a 3.92% reduction in annual spread¹⁵ (Level 1.b evidence).

Chemotherapy adverse events

- Six RCTs found there were no serious adverse events associated with albendazole, ivermectin or DEC. In one RCT that used much higher doses of medications there was a high incidence of scrotal syndrome (scrotal pain, epididymis enlargement and fever) in participants with albendazole² (Level 1.c evidence).
- When compared to no treatment, DEC-medicated salt was associated with increased mild symptoms (details not reported) in one study. In a before-and-after study, DEC-medicated salt was associated with mild headache, nausea and lymphangitis. In 19 other studies there were no adverse effects associated with DEC-medicated salts¹⁵ (Level 1.b evidence).

CHARACTERISTICS OF THE EVIDENCE

This evidence summary is based on a structured database search using the search terms lymphoedema, filariasis, lymphatic filariasis and Bancroftian filariasis. The evidence comes from:

- A systematic review of RCTs² (Level 1.a).
- A systematic review including trials of various methodologies¹⁵ (Level 1.b).
- RCTs (some reported in the above systematic reviews)⁸⁻¹³ (Level 1.c).
- A case series study⁵ (Level 4.c).
- A cross-sectional study¹ (Level 4.b).
- Opinion-based resources^{3,4,6,7,14} (Level 5.b).

BEST PRACTICE RECOMMENDATIONS

- In geographic regions with filariasis, implement vector control strategies including mosquito netting, mosquito repellent and covering the skin (Grade A).
- In geographic regions with filariasis, an annual single dose of combination therapy (albendazole plus either diethylcarbamazine or ivermectin) or six to 12 months of DEC-medicated salt should be implemented to reduce the spread of disease (Grade A).

REFERENCES

1. Lemnge MM, Mmbando BP, Segeja MD, Gesase S, Bygbjerg IC. Impact of insecticide treated mosquito nets and low dose monthly diethylcarbamazine on lymphatic filariasis infection between 1999 and 2004 in two endemic communities of north-eastern Tanzania. *Tanzan J Health Res* 2012; 14(3):1–12. (Level 4.b evidence).
2. Addiss D, Gamble CL, Garner P, Gelband H, Ejere HOD, Critchley JA, International Filariasis Review Group. Albendazole for lymphatic filariasis. *Cochrane Database Syst Rev* 2005; Issue 4, Art. No.: CD003753. DOI: 10.1002/14651858.CD003753.pub3. (Level 1.a evidence).
3. Centers for Disease Control and Prevention. 2011–2014. Lymphatic Filariasis. Available from: <http://www.cdc.gov/parasites/lymphaticfilariasis/>. [Accessed 2015 August] (Level 5.b evidence).
4. World Health Organization (WHO). Lymphatic filariasis (Fact sheet no. 102). WHO, 2015. Available from: <http://www.who.int/mediacentre/factsheets/fs102/en/>. [Accessed 2015 August] (Level 5.b evidence).
5. Addiss DG, Louis-Charles J, Roberts J, LeConte F, Wendt JM, Milord MD, Lammie PJ, Dreyer G. Feasibility and effectiveness of basic lymphedema management in Leogane, Haiti, an area endemic for Bancroftian filariasis. *PLoS Negl Trop Dis* 2010; 4(4):e668. (Level 4.c evidence).
6. Mendoza N, Li A, Gill A, Tying S. Filariasis: diagnosis and treatment. *Dermatol Ther* 2009; 22:475–90. (Level 5.b evidence).
7. World Health Organization (WHO). Filariasis. WHO, 2015. Available from: <http://www.who.int/topics/filariasis/en/>. [Accessed] (Level 5.b evidence).
8. Beach MJ, Streit TG, Addiss DG, Prospere R, Roberts JM, Lammie PJ. Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and *Wuchereria bancrofti* infections in Haitian school children. *Am J Trop Med Hyg* 1999; 60(3):479–86. (Level 1.c evidence).
9. Dunyo SK, Nkrumah FK, Simonsen PE. A randomized double-blind placebo-controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. *Trans R Soc Trop Med Hyg* 2000; 94(2):205–11. (1.c evidence).
10. Fox LM, Furness BW, Haser JK, Desire D, Brissau JM, Milord MD, *et al.* Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of *Wuchereria bancrofti* and intestinal helminth infections in Haitian children. *Am J Trop Med Hyg* 2005; 73(1):115–21; reported in Addiss D, Gamble CL, Garner P, Gelband H, Ejere HOD, Critchley JA & International Filariasis Review Group. Albendazole for lymphatic filariasis. *Cochrane Database Syst Rev* 2005; Issue 4, Art. No.: CD003753. DOI: 10.1002/14651858.CD003753.pub3. (1.c evidence).
11. Kshirsagar NA, Gogtay NJ, Garg BS, Deshmukh PR, Rajgor DD, Kadam VS *et al.* Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co-administration in a field study in an area endemic for lymphatic filariasis in India. *Trans R Soc Trop Med Hyg* 2004; 98(4):205–17. (Level 1.c evidence).
12. Pani SP, Reddy SR, Das LK, Vanamail P. Efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co-administration of both in clearance of *Wuchereria bancrofti* microfilarial and adult parasites in asymptomatic microfilaremic volunteers: Results of two-year follow-up. *Indian Journal of Lymphology* 2004; 2:20–3. (Level 1.c evidence).
13. Simonsen PE, Magesa SM, Dunyo SK, Malecela-Lazaro MN, Michael E. The effect of single dose ivermectin alone or in combination with albendazole on *Wuchereria bancrofti* infection in primary school children in Tanzania. *Trans R Soc Trop Med Hyg* 2004; 98(8):462–72, reported in Addiss D, Gamble CL, Garner P, Gelband H, Ejere HOD, Critchley JA & International Filariasis Review Group. Albendazole for lymphatic filariasis. *Cochrane Database Syst Rev* 2005; Issue 4, Art. No.: CD003753. DOI: 10.1002/14651858.CD003753.pub3. (Level 1.c evidence).
14. Bockarie MJ. Elimination of lymphatic filariasis: do we have the drugs to complete the job? *Curr Opin Infect Dis* 2010; 23:616–20. (Level 5.b evidence).
15. Adinarayanan S, Critchley JA, Das PK, Gelband H. Diethylcarbamazine (DEC)-medicated salt for community-based control of lymphatic filariasis. *Cochrane Database Syst Rev* 2007; 1:Art. No.: CD003758. DOI: 10.1002/14651858.CD003758.pub2. (Level 1.b evidence).